RenovoRx Inc. (RNXT) announced the pricing of a firm commitment, underwritten public offering of about 11.52 million shares of its ...
RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing novel targeted oncology therapies and commercializing ...
MOUNTAIN VIEW, Calif. - RenovoRx , Inc. (NASDAQ:RNXT), a $35.7 million market cap developer of targeted oncology therapies, has initiated an underwritten public offering of its common stock and ...
Volcon, Inc. (Nasdaq:VLCN) (the “Company”), the first all-electric, off-road powersports company, today announced that it has commenced a public offering to offer and sell securities, including shares ...
Akero Therapeutics announced a public offering of over 5.3 million shares at $48 each, aiming for $350 million in proceeds. Akero Therapeutics, Inc. has announced a public offering of 5,333,420 ...
Nuvectis Pharma (NVCT) announced the pricing of its previously announced underwritten public offering of 2,700,000 shares of its common stock at a ...
In addition, Akero intends to grant the underwriters a 30-day option to purchase up to an additional $45.0 million of shares of its common stock at the public offering price, less underwriting ...